Sunterra Bio, Inc. is a biotechnology company developing novel inhaled small-molecule therapies for progressive and life-threatening pulmonary diseases. Our lead product candidate, SUN-001, is a first-in-class dual BRD4 and p300 inhibitor that harnesses the pleiotropic and anti-fibrotic properties of epigenetic modulation while minimizing the systemic toxicities typically associated with oral administration.

We are committed to advancing innovative treatment approaches for patients living with life-threatening pulmonary conditions. For more information, visit www.sunterrabio.com.

Sunterra Bio

Org chart

Teams

Offices